Key Takeaways
- • Chemify, the Glasgow-based digital chemistry company, appointed Rima Alameddine to its Board of Directors as an independent non-executive director, according to a Business Wire release.
- • Alameddine most recently served as Chief Revenue Officer of IonQ from 2022 to 2025, leading its global go-to-market organisation, and previously spent nearly seven years at NVIDIA as Vice President of Enterprise Sales.
- • The appointment follows Chemify's announced £89.9 million expansion, supported by £22 million from Scottish Enterprise and the UK Government, for a new global headquarters and R&D centre in Govan that is expected to create up to 300 jobs.
- • Chemify's Series B round, co-led by Wing Venture Capital and Insight Partners, has been extended to £51.9 million, bringing total funding raised to more than £110 million.
Summary
Chemify has appointed Rima Alameddine to its Board of Directors as an independent non-executive director, the company announced via Business Wire. Alameddine brings roughly three decades of experience commercialising technologies across the internet era at Cisco, the rise of AI at NVIDIA, and the emergence of quantum computing at IonQ. She spent 18 years at Cisco in engineering and sales leadership roles, including leading its New York enterprise business, before joining NVIDIA, where she spent nearly seven years as Vice President of Enterprise Sales. She subsequently served as Chief Revenue Officer of IonQ from 2022 to 2025.
The appointment comes as Chemify moves into its next growth phase. In September the company announced an £89.9 million expansion, supported by £22 million from Scottish Enterprise and the UK Government, to establish a new global headquarters and research and development centre at the University of Glasgow's Health Innovation Hub in Govan, with up to 300 new jobs planned. The company's Series B round, co-led by Wing Venture Capital and Insight Partners, has been extended to £51.9 million, taking total funding to more than £110 million. Other backers include 8VC and Triatomic Capital.
Chemify, a spin-out from the University of Glasgow, combines AI, robotics and chemistry to design, make and scale molecules for medicines and advanced materials. Its chemputation technology, built on more than 20 years of research in the Cronin Group, converts chemical synthesis into automatically executable code. The company's first Chemifarm in Glasgow is operational.
Professor Lee Cronin, founder and CEO, said that while AI-driven chemistry design has advanced rapidly, the physical making of molecules has not, and that Chemify aims to close that gap. He described Alameddine's experience building enterprise sales at NVIDIA and taking quantum computing to enterprise customers at IonQ as directly relevant to the company's commercial goals as it builds what he called the first chemistry hyperscaler. Alameddine said she is delighted to join the board and help bring the platform, in which a molecule designed in software can be made, tested and scaled, to market.
Alameddine holds a Master's degree in Computer Engineering from Syracuse University and a Bachelor's degree in Computer and Communication Engineering from the American University of Beirut.
The appointment comes as Chemify moves into its next growth phase. In September the company announced an £89.9 million expansion, supported by £22 million from Scottish Enterprise and the UK Government, to establish a new global headquarters and research and development centre at the University of Glasgow's Health Innovation Hub in Govan, with up to 300 new jobs planned. The company's Series B round, co-led by Wing Venture Capital and Insight Partners, has been extended to £51.9 million, taking total funding to more than £110 million. Other backers include 8VC and Triatomic Capital.
Chemify, a spin-out from the University of Glasgow, combines AI, robotics and chemistry to design, make and scale molecules for medicines and advanced materials. Its chemputation technology, built on more than 20 years of research in the Cronin Group, converts chemical synthesis into automatically executable code. The company's first Chemifarm in Glasgow is operational.
Professor Lee Cronin, founder and CEO, said that while AI-driven chemistry design has advanced rapidly, the physical making of molecules has not, and that Chemify aims to close that gap. He described Alameddine's experience building enterprise sales at NVIDIA and taking quantum computing to enterprise customers at IonQ as directly relevant to the company's commercial goals as it builds what he called the first chemistry hyperscaler. Alameddine said she is delighted to join the board and help bring the platform, in which a molecule designed in software can be made, tested and scaled, to market.
Alameddine holds a Master's degree in Computer Engineering from Syracuse University and a Bachelor's degree in Computer and Communication Engineering from the American University of Beirut.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.